Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.

@article{Meyers2007Phosphodiesterase4I,
  title={Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.},
  author={John A. Meyers and Josephine Taverna and Jorge Chaves and Anthony Makkinje and Adam P Lerner},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2007},
  volume={13 16},
  pages={4920-7}
}
Type 4 cyclic AMP (cAMP) phosphodiesterase (PDE4) inhibitors, a class of compounds in clinical development that activate cAMP-mediated signaling by inhibiting cAMP catabolism, offer a feasible means by which to potentiate glucocorticoid-mediated apoptosis in lymphoid malignancies such as B-cell chronic lymphocytic leukemia (B-CLL). In this study, we show that PDE4 inhibitors up-regulate glucocorticoid receptor (GRalpha) transcript levels in B-CLL cells but not T-CLL cells or Sezary cells or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Translational regulatorymechanisms generate N - terminal glucocorticoid receptor isoforms with unique transcriptional target genes

CidlowskiJA LuNZ
Mol Cell • 2005

Threemecha - nismsareinvolvedinglucocorticoidreceptorautoregulation in a humanTlymphoblast cell line

KB Pedersen, CD Geng
Biochemistry • 2004

Similar Papers

Loading similar papers…